Cell studies of a three-component antisense MORF/tat/Herceptin nanoparticle designed for improved tumor delivery
Authors:
Open Access
- 14 December 2007
- journal article
- research article
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 15 (2) , 126-132
Abstract
The three-component nanoparticle of this investigation consisted of an anti-type I regulatory subunit α of the cyclic AMP-dependent protein kinase A (RIα) antisense phosphorodiamidate morpholino (MORF) oligomer, a tat peptide and the anti-HER2 Herceptin antibody each biotinylated and each linked via streptavidin and tested in SUM190 (HER2+), SUM149 (HER2−) and SK-BR-3 (HER2+) cells in culture, using both radioactivity and fluorescent labels on the antisense and control sense MORF. Within the nanoparticle, the antibody provides specific binding to the target cells, the tat improves cellular delivery and the MORF provides the specific retention of the radioactivity in the target cell nucleus. The results show that within the nanoparticle, the Herceptin was still able to bind to its determinant; that the MORF escaped entrapment with its mRNA-binding ability preserved and that the tat maintained its carrier function. Fluorescence microscopy showed evidence of antisense MORF internalization, separation from Herceptin and migration to the nucleus. In conclusion, streptavidin appears to provide an easy means of mixing and matching components to improve the tumor-specific targeting, cell membrane transport, pharmacokinetics and other properties of antisense and other oligomers. Combining the three components of this investigation with streptavidin apparently did not interfere with the properties of each component in cell culture and significantly improved delivery.Keywords
This publication has 16 references indexed in Scilit:
- Cell Culture and Xenograft-Bearing Animal Studies of Radiolabeled Antisense DNA Carrier Nanoparticles with Streptavidin as a LinkerJournal of Nuclear Medicine, 2007
- Simplified Preparation via Streptavidin of Antisense Oligomers/Carriers Nanoparticles Showing Improved Cellular Delivery in CultureBioconjugate Chemistry, 2007
- An improved synthesis of NHS-MAG3 for conjugation and radiolabeling of biomolecules with 99mTc at room temperatureNature Protocols, 2007
- In vivo Real-time Tracking of Single Quantum Dots Conjugated with Monoclonal Anti-HER2 Antibody in Tumors of MiceCancer Research, 2007
- Targeting of biotinylated oligonucleotides to prostate tumors with antibody-based delivery vehiclesJournal of Drug Targeting, 2007
- Aptamer mediated siRNA deliveryNucleic Acids Research, 2006
- Progress towards in Vivo Use of siRNAsMolecular Therapy, 2006
- A TAT–streptavidin fusion protein directs uptake of biotinylated cargo into mammalian cellsProtein Engineering, Design and Selection, 2005
- Electrostatic binding with tat and other cationic peptides increases cell accumulation of 99mTc-antisense DNAs without entrapmentMolecular Imaging and Biology, 2003
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neuOncogeneScience, 1987